24‐month overall survival from KEYNOTE‐021 cohort G: Pemetrexed‐carboplatin plus pembrolizumab as first‐line therapy for advanced nonsquamous NSCLC.

Authors
Category Primary study
Year 2018
This article has no abstract
Epistemonikos ID: 0ad9cdd9fc95a2ad6201f98d47d12759873b6b17
First added on: Oct 16, 2020